GLATIRAMER ACETATE INJECTION
MYLAN PHARMACEUTICALS ULC
Quick answers
Is there a shortage of GLATIRAMER ACETATE INJECTION in Canada?
No. There is no current shortage of GLATIRAMER ACETATE INJECTION 20MG reported to Health Canada. Stock can still vary from one pharmacy to another.
Other Products Containing the Same Active Ingredient
These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.
Closest Matches
COPAXONE
TEVA CANADA LIMITED
GLATECT
PHARMASCIENCE INC
⚠ Possible Recall or Safety Alert
Health Canada has issued a recall or safety alert matching this product. This match is based on product name similarity and may not be exact — confirm against your specific lot number before taking action.
COPAXONE (glatiramer acetate)
Important Safety Information on COPAXONE (glatiramer acetate) and the Risk of Anaphylactic Reactions Which May Occur at Any Time Following Initiation of Treatment
Possible match — not confirmed
Glatiramer acetate
Risk of anaphylactic reaction associated with glatiramer acetate, used to treat multiple sclerosis
Possible match — not confirmed
DIN
02541440
Strength
20MG
Dosage Form
Solution
Route
Subcutaneous
Compare with another product →
Shortage History
No shortage or discontinuation reports on file for this product.
Other Products from MYLAN PHARMACEUTICALS ULC
Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.
500MG · DIN 02385473
333MG · DIN 02293269
10MG · DIN 02257955
40MG · DIN 02257963
DIN 02388138
DIN 02388146
50MG · DIN 02468549
1G · DIN 02407302
2G · DIN 02407310
12.5MG · DIN 02554631
25MG · DIN 02247243
100MG · DIN 02247244